Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Pharmac is seeking public feedback on a proposal to fund a new, additional type of insulin for people with diabetes from 1 May 2025. The new medicine (branded as Ryzodeg) is a combination of two other ...

California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin ...

Type 1 Diabetes Market Rising Prevalence and Technological Advancements Drive Market Growth AUSTIN, TX, UNITED STATES, February 28, 202 ...

AS Heart Month reminds us of the critical need to protect our cardiovascular and metabolic health, Novo Nordisk Philippines and the Philippine College of Endocrinology, Diabetes and Metabolism (PCEDM) ...

The drugmaker Novo Nordisk can meet current and future demand in the U.S., the Food and Drug Administration said. But patients may still see some supply disruptions as the medications move from ...

as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar ...

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk’s NOVO.B0.51%increase; green up pointing triangle weight-loss medications Wegovy and Ozempic has been resolved ...